R Squared Ltd Boosts Position in Ironwood Pharmaceuticals, Inc. $IRWD

R Squared Ltd lifted its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 286.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,765 shares of the biotechnology company’s stock after purchasing an additional 28,735 shares during the quarter. R Squared Ltd’s holdings in Ironwood Pharmaceuticals were worth $28,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Armistice Capital LLC grew its holdings in shares of Ironwood Pharmaceuticals by 44.7% during the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company’s stock worth $20,139,000 after purchasing an additional 4,232,000 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 186.6% during the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Ironwood Pharmaceuticals by 740.5% during the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock worth $5,160,000 after purchasing an additional 3,092,475 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Ironwood Pharmaceuticals by 33.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,647,015 shares of the biotechnology company’s stock worth $3,891,000 after purchasing an additional 663,775 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 160.7% during the first quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company’s stock worth $3,878,000 after purchasing an additional 1,630,726 shares in the last quarter.

Ironwood Pharmaceuticals Price Performance

NASDAQ:IRWD opened at $1.66 on Monday. The business has a 50 day moving average of $1.37 and a 200 day moving average of $0.97. The company has a market capitalization of $269.63 million, a price-to-earnings ratio of -33.19 and a beta of 0.30. Ironwood Pharmaceuticals, Inc. has a 1-year low of $0.53 and a 1-year high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The firm had revenue of $85.24 million during the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on IRWD shares. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Ironwood Pharmaceuticals has an average rating of “Hold” and a consensus price target of $4.94.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.